Clinical Trial Update: Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Cediranib as palliative treatment for symptomatic malignant ascites or malignant pleural effusion; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ascites
• Malignant Pleural Effusion

Drugs mentioned

• Cediranib (Cediranib)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Malignant Ascites, Malignant Pleural Effusion | Phase 2 | Status: TERMINATED